Table 4 Treatment-emergent adverse events occurring in ≥10% of patients (safety population, N = 30)

Hypertension

11 (36.7%)

15 (50%)

26 (86.7%)

Palmar-plantar erthrodysesthesia syndrome

10 (33.3%)

9 (30%)

3 (10%)

22 (73.3%)

White blood cell decreased

12 (40%)

7 (23.3%)

2 (6.7%)

21 (70%)

Neutrophil count decreased

7 (23.3%)

5 (16.7%)

8 (26.7%)

20 (66.7%)

Vomiting

11 (36.7%)

2 (6.7%)

2 (6.7%)

15 (50%)

Decreased appetite

11 (36.7%)

4 (13.3%)

15 (50%)

Nausea

11 (36.7%)

2 (6.7%)

13 (43.3%)

Malaise

11 (36.7%)

1 (3.3%)

12 (40%)

Platelet count decreased

7 (23.3%)

2 (6.7%)

1 (3.3%)

2 (6.7%)

12 (40%)

Diarrhea

4 (13.3%)

2 (6.7%)

4 (13.3%)

10 (33.3%)

Peripheral neurotoxicity

8 (26.7%)

1 (3.3%)

1 (3.3%)

10 (33.3%)

Alanine aminotransferase increased

5 (16.7%)

3 (10%)

1 (3.3%)

9 (30.0%)

Aspartate aminotransferase increased

4 (13.3%)

2 (6.7%)

3 (10.0%)

9 (30.0%)

Constipation

4 (13.3%)

2 (6.7%)

6 (20%)

Toothache

5 (16.7%)

1 (3.3%)

6 (20%)

Fever

5 (16.7%)

5 (16.7%)

Abdominal pain

3 (10%)

1 (3.3%)

1 (3.3%)

5 (16.7%)

Thyroid-stimulating hormone increased

3 (10%)

1 (3.3%)

4 (13.3%)

Hypertriglyceridemia

1 (3.3%)

1 (3.3%)

2 (6.7%)

4 (13.3%)

Dizziness

4 (13.3%)

4 (13.3%)

Proteinuria

2 (6.7%)

1 (3.3%)

3 (10%)

Hypokalemia

2 (6.7%)

1 (3.3%)

3 (10%)

Hyponatremia

1 (3.3%)

1 (3.3%)

1 (3.3%)

3 (10%)

Cough

2 (6.7%)

1 (3.3%)

3 (10%)

Upper respiratory infection

3 (10%)

3 (10%)

Weight loss

1 (3.3%)

2 (6.7%)

3 (10%)

Headache

3 (10%)

3 (10%)